to reduce the likelihood of fatty plaques in arteries that can restrict blood flow and lead to heart attacks and strokes. So why will obicetrapib avoid the pitfalls of its predecessors?

So the plaques that get formed in the coronary arteries ... acid as well as a long acting injectable medication called inclisiran. The first thing I tell them it's probably not their fault.

More and more people are talking about Novartis over the last few weeks. Is it worth buying the Pharmaceutical stock at a price of $112.13? Only time will tell. The information below will give you a ...

Critics say a new, broader definition of high-risk plaque opens the door to more tests, diagnoses, and invasive procedures, steering us down a potentially harmful path.

Novartis is heading the pack with Leqvio (inclisiran), its PCSK9-targeting antisense drug for reducing cholesterol levels in the blood, but is being pursued by a competing drug from AstraZeneca ...

I joined the University of Sheffield in 2002 as a Senior Clinical Lecturer in Cardiology and subsequently became Professor of Cardiology in January 2011. I am Clinical Lead for the Cardiovascular ...

The presence, number, and size of plaques on carotid ultrasound in adults may, however, be useful in risk stratification. 34 Measures of abdominal atherosclerosis have also not been well studied. CIMT ...

Treatment of familial hypercholesterolemia is directed toward the moment of the medical encounter. However, risk for heart disease as a consequence of having familial hypercholesterolemia is related ...

Pre-Market: 8:04:50 a.m. EDT Loading Chart for NVS ...

As of 1:32:28 pm GMT-4. Market open. Loading Chart for NVS ...